tuneTypical Dose
1–2 g/day
Amino Acid
L-Carnosine
L-Carnosine (β-alanyl-L-histidine)
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Clinical biomarker signals commonly emerge within 8-14 weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
L-carnosine is a dipeptide found in muscle and brain with antioxidant and antiglycation activity. It is used for metabolic aging support and for reducing oxidative and glycation stress biomarkers.
Human studies suggest modest improvements in oxidative stress and glycation-related biomarkers, with small signals for glucose metabolism support in some groups. Topical or oral use may benefit skin appearance measures. Minority evidence explores neuroprotective and cataract-related effects, mostly preclinical. Net benefit appears modest and more evident in metabolic risk or higher oxidative stress states.
Proposed anti-glycation and redox-modulating effects may reduce glucose and kidney injury signals in selected dysglycaemic settings. Direct nootropic and performance effects are not consistently replicated in clinical trials.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Improvement in OGTT glucose metrics in prediabetes/T2DM (short-term RCT signal).
- Reduction in urinary albumin/oxidative markers in pediatric diabetic nephropathy RCT.
- No reliable cognitive improvement signal in one RCT context despite mechanistic rationale.
Secondary Outcomes
- Potential adjunct benefit for depression scales with citalopram in one small RCT.
- No robust evidence of direct exercise performance enhancement from oral L-carnosine trials.
Safety
Contraindications and Interactions
Contraindications
- Pregnancy
- Lactation
- High-risk comorbid disease
Side effects
- Generally well tolerated
- Rare tingling
Interactions
- Limited direct interaction data. Monitor with CNS and psychiatric medications
Avoid if
- Active malignancy
- Unstable cardiovascular or psychiatric disease
Evidence
Study-level References
l-carnosine-SRC-001Randomized controlled trial
Sourceopen_in_newHariharan R et al., "Carnosine supplementation improves glucose control in adults with pre-diabetes and type 2 diabetes: A randomised controlled trial", PMID 38172006, DOI: 10.1016/j.numecd.2023.10.012
Population: Trial participants on standard diabetes care; glucose tolerance and OGTT metrics tracked
Dose protocol: 2 g/day L-carnosine, 14 weeks
Key findings: Reduced 90-min and 120-min OGTT glucose and glucose AUC versus placebo. No insulin-secretion change signal reported as primary biochemical driver.
Notes: Moderate. Randomization and placebo control are strengths, but external generalizability is limited.
Paper content
Reduced 90-min and 120-min OGTT glucose and glucose AUC versus placebo; no insulin-secretion change signal reported as primary biochemical driver.
l-carnosine-SRC-002Randomized, placebo-controlled trial
Sourceopen_in_newElbarbary et al., pediatric diabetic nephropathy RCT, PMID 28744992
Population: Urinary albumin/oxidative stress outcomes under standard background ACE-inhibitor therapy
Dose protocol: 1 g/day L-carnosine, 12 weeks
Key findings: Directionally favorable renal injury biomarkers and TAC/MDA shifts with no severe adverse signals reported.
Notes: Small-sample and short-duration design. Long-term renal outcomes unproven.
Paper content
Directionally favorable renal injury biomarkers and TAC/MDA shifts with no severe adverse signals reported.
l-carnosine-SRC-003Randomized, double-blind, placebo-controlled adjunct trial
Sourceopen_in_newAraminia et al., "L-Carnosine combination therapy for major depressive disorder..." PMID 32063564, DOI: 10.1016/j.jad.2020.02.020
Population: HAM-D outcomes with adjunctive regimen
Dose protocol: 400 mg twice daily + citalopram, 6 weeks
Key findings: HAM-D improved faster/more than placebo. Response/remission rates favored L-carnosine adjunct arm. Safety acceptable in this study.
Notes: Underpowered for safety/rare events and broad generalization.
Paper content
HAM-D improved faster/more than placebo; response/remission rates favored L-carnosine adjunct arm; safety acceptable in this study.
l-carnosine-SRC-004Randomized, double-blind controlled secondary analysis
Sourceopen_in_newHariharan et al. secondary analysis from Carnosine RCT, PMID 39770949
Population: Strength and bone outcomes only (no cognitive-focused primary endpoint in this paper)
Dose protocol: 2 g/day L-carnosine, 14 weeks
Key findings: No meaningful changes in hand-grip strength, body composition, or tibial bone outcomes.
Notes: Useful for limiting over-claiming on performance claims, but not designed for all endpoints.
Paper content
No meaningful changes in hand-grip strength, body composition, or tibial bone outcomes.
l-carnosine-SRC-005Cochrane systematic review (with trial-level RCT evidence review)
Sourceopen_in_newCrossover/aggregated trial review of N-acetylcarnosine for cataract: PMCID PMC6464029, PMID 28245346, DOI: 10.1002/14651858.CD009493
Population: Topical N-acetylcarnosine eye-drop evidence, not oral systemic L-carnosine
Dose protocol: Heterogeneous topical trial protocols across historical studies
Key findings: Evidence judged insufficient for cataract progression benefit. No clear visual-function endpoint certainty.
Notes: Historical methodological limits and heterogeneity reduce confidence for systemic claims.
Paper content
Evidence judged insufficient for cataract progression benefit; no clear visual-function endpoint certainty.
l-carnosine-SRC-006Randomized, placebo-controlled trial
Sourceopen_in_newHariharan et al., cognitive outcomes RCT, PMID 40430451, DOI: 10.3390/ph18050630
Population: Computerized cognitive battery and executive-function outcomes
Dose protocol: Study-dose and period consistent with carnosine diabetes cohort design
Key findings: No significant cognitive improvements vs placebo across measured domains. Supports conservative framing for nootropic claims.
Notes: Null result is informative but limited by sample and specific population context.
Paper content
No significant cognitive improvements vs placebo across measured domains; supports conservative framing for nootropic claims.
l-carnosine-SRC-007Double-blind, randomized, placebo-controlled trial.
Sourceopen_in_newSaadati S, et al. Carnosine Supplementation Has No Effect on Inflammatory Markers in Adults with Prediabetes and Type 2 Diabetes: A Randomized Controlled Trial. Nutrients. 2024;16(22):3900. doi:10.3390/nu16223900. PMID:39599686.
Population: Adults with prediabetes or well-controlled type 2 diabetes.
Dose protocol: 2 g/day carnosine versus placebo for 14 weeks in adults with prediabetes or T2DM.
Key findings: No significant between-group differences in pro-inflammatory or anti-inflammatory cytokines or adipokines.
Notes: Informative null result that limits anti-inflammatory claims for carnosine in metabolic populations. Same cohort design as glucose-tolerance trial.
Paper content
This double-blind RCT tested 2 g/day carnosine versus placebo for 14 weeks in adults with prediabetes or T2DM. Changes in pro-inflammatory and anti-inflammatory cytokines and adipokines did not differ between groups, even after adjusting for confounders. This null result is important because it limits the mechanistic narrative that carnosine's anti-glycation properties translate to measurable anti-inflammatory effects in this metabolic population at this dose and duration. The authors note that longer trials in patients with poorly controlled diabetes may yield different results.